Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Anthracyclines were basic drugs in lymphoma treatment. However, their dose accumulation
related cardiac toxicity limits their clinical application, especially adriamycin. Adriamycin
has been gradually replaced by epirubicin. Polyethylene glycol liposome doxorubicin (PLD) can
go into tumor tissues through tumor angiogenesis and produces targeted killing effect to
tumor tissues. PLD has potential advantages in the treatment of malignant tumors,including
lymphoma.